Curated News
By: NewsRamp Editorial Staff
September 17, 2026
Quantum BioPharma Gets Buy Rating, $8 Target from Rodman & Renshaw
TLDR
- Quantum BioPharma received a Buy rating and $8 price target from Rodman & Renshaw, signaling potential upside for investors.
- Rodman & Renshaw initiated coverage on Quantum BioPharma, citing its drug candidates for neurodegenerative and metabolic disorders.
- Quantum BioPharma advances treatments for multiple sclerosis and alcohol misuse, aiming to improve lives and health outcomes.
- Quantum BioPharma's UNBUZZD spinout retains a 7% royalty on sales until reaching $250 million, then 3% perpetually.
Impact - Why it Matters
The initiation of coverage by Rodman & Renshaw with a Buy rating and an $8 price target shines a spotlight on Quantum BioPharma's promising pipeline, particularly its lead compound Lucid-MS for multiple sclerosis and its innovative UNBUZZD product for alcohol misuse. This validation from a respected analyst could boost investor confidence and attract new capital, which is crucial for advancing clinical development. For patients suffering from neurodegenerative disorders and alcohol misuse, this news signals potential progress toward new treatment options. Furthermore, it underscores the growing interest in biotech companies that are tackling unmet medical needs, and it highlights the role of specialized communications platforms like MissionIR in enhancing visibility for such companies within the investment community. As Quantum continues to develop its assets, the recognition from Rodman & Renshaw may serve as a catalyst for further growth and partnerships.
Summary
Quantum BioPharma Ltd., a biopharmaceutical company developing treatments for neurodegenerative and metabolic disorders and alcohol misuse disorders, has received a significant vote of confidence from Rodman & Renshaw. The investment firm initiated coverage on the company with a Buy rating and an $8 price target. The research report was led by Michael G. King Jr., director of research and senior biotechnology analyst at Rodman & Renshaw. Quantum BioPharma emphasized that the coverage is unpaid and that it provided no consideration or fees for the report. The company, which trades on NASDAQ under the ticker QNTM, is dedicated to building a portfolio of innovative assets and biotech solutions, with drug candidates in various stages of development.
Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., Quantum is focused on the research and development of its lead compound, Lucid-MS. This patented new chemical entity has shown promise in preclinical models by preventing and reversing myelin degradation, the underlying mechanism of multiple sclerosis. Additionally, Quantum invented UNBUZZD, an over-the-counter product spun out to Unbuzzd Wellness Inc. Quantum retains a 19.84% ownership stake in Unbuzzd as of March 31, 2026, and is entitled to royalty payments of 7% of sales until payments total $250 million, after which the royalty drops to 3% in perpetuity. The company also retains 100% of the rights to develop similar products for pharmaceutical and medical uses.
The coverage by Rodman & Renshaw highlights the potential of Quantum’s pipeline and could draw increased investor attention to the company. For more information, the full press release is available at https://ibn.fm/6Lqsb. Quantum BioPharma’s latest news and updates can be found in the company’s newsroom. This announcement was disseminated through MissionIR, a specialized communications platform that is part of the Dynamic Brand Portfolio @ IBN, which provides access to a vast network of wire solutions via InvestorWire, among other services.
Source Statement
This curated news summary relied on content distributed by InvestorBrandNetwork (IBN). Read the original source here, Quantum BioPharma Gets Buy Rating, $8 Target from Rodman & Renshaw
